Preoperative small airway dysfunction is associated with skeletal muscle loss in early-stage non-small cell lung cancer

被引:2
|
作者
Jia, Qing-chun [1 ]
Niu, Ye [1 ]
Qin, Ling [2 ]
Yuan, Jia-rui [1 ]
Liu, Ping-ping [1 ]
Liu, Le [1 ]
Miao, Shi-di [3 ]
Wang, Rui-tao [1 ,5 ]
Meng, Qing-wei [4 ,6 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Internal Med, Harbin 150081, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Dept Pathol, Harbin 150081, Heilongjiang, Peoples R China
[3] Harbin Univ Sci & Technol, Sch Comp Sci & Technol, Harbin 150080, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin 150081, Heilongjiang, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Dept Internal Med, 150 Haping ST, Harbin 150081, Peoples R China
[6] Harbin Med Univ, Canc Hosp, Dept Med Oncol, 150 Haping ST, Harbin 150081, Peoples R China
关键词
Small airway dysfunction; Non-small cell lung cancer; Skeletal muscle loss; SARCOPENIC OBESITY; PREVALENCE; PROGNOSIS;
D O I
10.1016/j.clnu.2023.08.002
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Postoperative skeletal muscle loss (SM loss) was reported to be associated with a poor prognosis in early-stage non-small cell lung cancer (NSCLC). Small airway dysfunction (SAD) is a common but neglected respiratory abnormality. Little information is known about the association between preoperative SAD and postoperative SM loss in early-stage NSCLC. Therefore, this study aimed to investigate the correlation between preoperative SAD and SM loss after surgery in early-stage NSCLC patients. Methods: There were 348 NSCLC patients with stages I-IIIA in this study from January 2017 to December 2020. All CT images were contrast-enhanced scans, and the skeletal muscle index (SMI) was measured using CT images. A 10.0% decrease in SMI over 12 months was determined as the cut-off value to define excessive SM loss. Logistic regression analyses were used to examine the relationship between SAD and SM loss. Results: This study included 348 subjects who underwent pulmonary operation (159 males and 189 females; mean age: 57.5 +/- 8.8 years). 152 (43.7%) patients were identified as having SAD before surgery, and 179 patients (51.4%) were identified as having SM loss after 1 year. Moreover, a higher incidence of SAD was found in the SM loss group compared with that in the non-SM loss group (52.0% vs. 34.9%, p = 0.001). The patients with SAD were older, had larger tumor size, and had lower albumin levels. Furthermore, there were significant correlations between the lung function parameters manifesting SAD and the percentage change in SMI (for the forced expiratory flow when 75% of forced vital capacity has been exhaled (FEF75%), Pearson r = -0.107, p = 0.046; for FEF50%, r = -0.142, p = 0.008; and for FEF25-75%, r = -0.124, p = 0.021; respectively). However, no significant correlations were found between SMI and the lung function parameters reflecting proximal airway obstruction (p > 0.05). Logistic regression analysis revealed that preoperative SAD (HR, 2.465; 95% CI, 1.256-4.838; p = 0.009) was independent risk factor for postoperative SM loss in early-stage NSCLC. In addition, multivariable analysis revealed that SAD (HR, 1.816; 95% CI, 1.025-3.216, P = 0.041) were associated with postoperative complications. Conclusion: Preoperative SAD is significantly associated with postoperative complications and SM loss in early NSCLC patients. Our results suggest that preoperative assessment of SAD may be useful for risk stratification of surgical candidates with potential for targeted interventions. (c) 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
引用
收藏
页码:1932 / 1939
页数:8
相关论文
共 50 条
  • [21] Health behaviors of early-stage non-small cell lung cancer survivors
    Paul Krebs
    Elliot J. Coups
    Marc B. Feinstein
    Jack E. Burkhalter
    Richard M. Steingart
    Amy Logue
    Bernard J. Park
    Jamie S. Ostroff
    Journal of Cancer Survivorship, 2012, 6 : 37 - 44
  • [22] Immunotherapy for early-stage non-small cell lung cancer: A system review
    Gao, Jingyi
    Zhang, Chao
    Wei, Zhigang
    Ye, Xin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 849 - 865
  • [23] Health behaviors of early-stage non-small cell lung cancer survivors
    Krebs, Paul
    Coups, Elliot J.
    Feinstein, Marc B.
    Burkhalter, Jack E.
    Steingart, Richard M.
    Logue, Amy
    Park, Bernard J.
    Ostroff, Jamie S.
    JOURNAL OF CANCER SURVIVORSHIP, 2012, 6 (01) : 37 - 44
  • [24] Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer
    Shin, Jacob Y.
    Yoon, Ja Kyoung
    Marwaha, Gaurav
    LUNG, 2018, 196 (03) : 351 - 358
  • [25] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [26] Is Brain MRI Unnecessary for Early-Stage Non-Small Cell Lung Cancer?
    Bizzi, Alberto
    Pascuzzo, Riccardo
    RADIOLOGY, 2022, 303 (03) : 644 - 645
  • [27] Disparities in surgical resection of early-stage non-small cell lung cancer
    Jazieh, AR
    Kyasa, MJ
    Sethuraman, G
    Howington, J
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (06): : 1173 - 1176
  • [28] Waiting times in early-stage non-small cell lung cancer (NSCLC)
    Saint-Jacques, Nathalie
    Rayson, Daniel
    Al-Fayea, Turki
    Virik, Kiran
    Morzycki, Wojciech
    Younis, Tallal
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 865 - 870
  • [29] EARLY-STAGE NON-SMALL CELL LUNG CANCER STRATIFYING RECURRENCE RISK
    Saito, T.
    Kono, Y.
    Ueno, Y.
    Maru, N.
    Utsumi, T.
    Matsui, H.
    Taniguchi, Y.
    Hino, H.
    Tsuta, K.
    Honda, O.
    Murakawa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S559 - S560
  • [30] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638